Neurocrine Biosciences

Neurocrine Biosciences

NBIX· Manufacturing· Fiscal year ends in December

CEO pay in FY2023Stock +10.3% in FY2023

Kyle W. Gano, Ph.D. is the CEO of Neurocrine Biosciences and was paid $6.0M in FY2023 (Dec), up 10%.

Pay$100 in the stock at the end of FY19 → $123
CEO pay is from each Neurocrine Biosciences proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives5

See all
  1. 1Jude OnyiaFY2023
  2. 2Sanjay Keswani, M.D.FY2023
  3. 3Matthew C. AbernethyFY2023
  4. 4Kyle W. Gano, Ph.D.FY2023
  5. 5Eric BenevichFY2022

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Neurocrine Biosciences paid its one named executive on file $16.0M in FY2024 (Dec).

Name
Jude OnyiaNot disclosed
Sanjay Keswani, M.D.Chief Medical Officer Jude Onyia, Ph.D.Not disclosedNot disclosed
Matthew C. AbernethyChief Financial OfficerNot disclosed
Kyle W. Gano, Ph.D.Chief Executive OfficerNot disclosed
Eric BenevichChief Commercial OfficerNot disclosedNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers18

See all

The FY2022 (Dec) proxy of Neurocrine Biosciences names 18 peer companies for pay. Among Neurocrine Biosciences and these peers, CEO pay was the lowest of 2 and total shareholder return was the highest of 2.

2nd highest of 2in Neurocrine Biosciences and its pay peers, FY2022 (Dec) by CEO pay:

$11.9M$16.7M

1st highest of 2in Neurocrine Biosciences and its pay peers, FY2022 (Dec) by total shareholder return:

$92$111

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board5

See all
  • Gary LyonsDirector · 32 yr on the boardIndependentScience and Medical Technology—Paid as an executive
  • Richard F. PopsDirector · 27 yr on the boardIndependentCompensation (Chair), Science and Medical Technology—Paid as an executive
  • Stephen A. Sherwin, M.D.Director · 26 yr on the boardIndependentAudit, Science and Medical Technology (Chair)—Paid as an executive
  • Shalini SharpDirector · 5 yr on the boardIndependentAudit (Chair), Compensation—Paid as an executive
  • Johanna MercierDirector · 4 yr on the boardIndependentCorporate Governance—Paid as an executive

The board of the latest proxy (FY2025).

Shared directors

Activity

  1. Pay
    Neurocrine Biosciences CFO pay rose 23% to $6.1M. The stock rose 10% in FY2023 (Dec).
    DEF 14A
  2. Pay
    Neurocrine Biosciences CEO pay rose 10% to $6.0M. The stock rose 10% in FY2023 (Dec).
    DEF 14A
  3. Pay
    Neurocrine Biosciences CEO pay fell 19% to $5.8M. The stock fell 11% in FY2021 (Dec).
    DEF 14A
  4. Pay
    Neurocrine Biosciences Director pay rose 32% to $15.8M. The stock rose 10% in FY2023 (Dec).
    DEF 14A
  5. Pay
    Pay for Jude Onyia at Neurocrine Biosciences rose 193% to $7.2M. The stock rose 10% in FY2023 (Dec).
    DEF 14A
  6. Pay
    Pay for Jude Onyia at Neurocrine Biosciences fell 68% to $2.5M. The stock rose 40% in FY2022 (Dec).
    DEF 14A
  7. Pay
    Neurocrine Biosciences CFO pay fell 17% to $4.9M. The stock rose 40% in FY2022 (Dec).
    DEF 14A
  8. Pay
    Neurocrine Biosciences Director pay fell 15% to $11.9M. The stock rose 40% in FY2022 (Dec).
    DEF 14A
  9. Pay
    Pay for Eiry W. Roberts, M.D. at Neurocrine Biosciences fell 11% to $5.7M. The stock rose 40% in FY2022 (Dec).
    DEF 14A
  10. Pay
    Neurocrine Biosciences General counsel pay fell 16% to $4.7M. The stock rose 40% in FY2022 (Dec).
    DEF 14A

Filings7

See all
Proxy statementDEF 14AApr 15, 2026FY2025
Annual report10-KFeb 11, 2026FY2025
Proxy statementDEF 14AApr 9, 2025FY2024
Annual report10-KFeb 10, 2025FY2024
Proxy statementDEF 14AApr 10, 2024FY2023
Annual report10-KFeb 9, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data